Direkt zum Inhalt
Merck
  • Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

Journal of medicinal chemistry (2005-03-04)
Steven Harper, Barbara Pacini, Salvatore Avolio, Marcello Di Filippo, Giovanni Migliaccio, Ralph Laufer, Raffaele De Francesco, Michael Rowley, Frank Narjes
ZUSAMMENFASSUNG

Allosteric inhibition of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase enzyme has recently emerged as a viable strategy toward blocking replication of viral RNA in cell-based systems. We report here a novel class of allosteric inhibitor of NS5B that shows potent affinity for the NS5B enzyme and effective inhibition of subgenomic HCV RNA replication in HUH-7 cells. Inhibitors from this class have promising characteristics for further development as anti-HCV agents.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Methyl-4-brom-3-methylbenzoat, 95%